Overview A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients Status: COMPLETED Trial end date: 2024-11-20 Target enrollment: Participant gender: Summary To assess the effectiveness of HSK7653 tablets following the substitution of daily DPP-4 inhibitor (DPP-4i) over a 24-week treatment period.Phase: PHASE2 Details Lead Sponsor: Haisco Pharmaceutical Group Co., Ltd.